Recombinant Pig MGP Protein，His & GST

MGP, or Matrix Gla Protein, is a vitamin K-dependent protein that plays a crucial role in regulating mineralization processes in the body, particularly in vascular and bone tissues. It is primarily expressed in bone and cartilage, where it inhibits the deposition of calcium phosphate crystals, thereby preventing calcification and contributing to proper skeletal development and cardiovascular health. Research into MGP has gained significant attention due to its implications in various diseases, including osteoporosis, vascular calcification, and arteriosclerosis. Studies have shown that reduced levels of MGP are associated with increased vascular stiffness and calcification, which are risk factors for cardiovascular diseases. Furthermore, MGP is involved in the inhibition of excessive mineralization, making it a potential target for therapeutic interventions aimed at treating or preventing mineral-related disorders. Understanding the mechanisms by which MGP functions, its regulatory pathways, and the influence of factors like vitamin K status and genetic polymorphisms is essential for developing strategies to harness its protective effects in health and disease. Researchers are exploring recombinant MGP (rMGP) as a promising avenue for therapeutic applications, aiming to utilize its properties to mitigate the adverse effects of dysregulated mineralization in various contexts. Overall, the comprehensive study of MGP and its recombinant forms holds significant potential for advancing our understanding of mineral metabolism and enhancing treatment options for related pathological conditions.